Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$5.38M-$5.38MN/M vs Q2 2021 EPS Diluted-$0.13-$0.13N/M vs Q2 2021 Operating Income-$5,401,000N/M Operating Cash Flowderived-$5,333,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end